Activation of beta 2-adrenergic receptors and ventricular fibrillation.
Billman
G E
GE
Department of Physiology, Ohio State University, Columbus, USA.
Altschuld
R A
RA
D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002986:Clinical Trials as Topic; D004285:Dogs; D004983:Ethanolamines / Q000494:pharmacology / Q000627:therapeutic use; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D009206:Myocardium / Q000378:metabolism; D010215:Papio; D011412:Propanolamines / Q000494:pharmacology / Q000627:therapeutic use; D011898:Ranidae; D051381:Rats; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects* / Q000502:physiology*; D013268:Stimulation, Chemical; D014693:Ventricular Fibrillation / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*
D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; D011412:Propanolamines; D018343:Receptors, Adrenergic, beta-2; C026777:ICI 118551; C002904:zinterol; D002118:Calcium